Document is current
Any future updates will be listed below
-
Authors
Cyr, Matthew G https://orcid.org/0000-0003-0312-4300
Mhibik, Maissa https://orcid.org/0000-0003-0733-3046
Qi, Junpeng
Peng, Haiyong https://orcid.org/0000-0003-0312-1337
Chang, Jing
Gaglione, Erika M
Eik, David
Herrick, John
Venables, Thomas
Novick, Scott J
Courouble, Valentine V https://orcid.org/0000-0001-5953-7767
Griffin, Patrick R
Wiestner, Adrian
Rader, Christoph https://orcid.org/0000-0001-9955-3454
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00923507 at ClinicalTrials.govnct00923507 at ClinicalTrials.govDocuments that mention this clinical trial
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia
https://doi.org/10.1136/jitc-2022-004850
nct01500733 at ClinicalTrials.govDocuments that mention this clinical trial
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia
https://doi.org/10.1136/jitc-2022-004850
nct02337829 at ClinicalTrials.govDocuments that mention this clinical trial
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia
https://doi.org/10.1136/jitc-2022-004850
nct00923507 at ClinicalTrials.govDocuments that mention this clinical trial
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia
https://doi.org/10.1136/jitc-2022-004850
nct01500733 at ClinicalTrials.govDocuments that mention this clinical trial
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia
https://doi.org/10.1136/jitc-2022-004850
nct02337829 at ClinicalTrials.govDocuments that mention this clinical trial
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia
https://doi.org/10.1136/jitc-2022-004850
Documents that mention this clinical trial
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia
https://doi.org/10.1136/jitc-2022-004850
-
Funding
Funding for this research was provided by:
National Cancer Institute (R01 CA174844)
National Cancer Institute (R21 CA229961)
National Heart, Lung, and Blood Institute (Intramural Research Program)
National Center for Advancing Translational Sciences (TL1 TR002551)
National Center for Advancing Translational Sciences (UL1 TR002550)
- License Information
